Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes
Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is ge...
Gespeichert in:
| Veröffentlicht in: | Clinical Epileptology 2024-02, Vol.37 (1), p.68-78 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 78 |
|---|---|
| container_issue | 1 |
| container_start_page | 68 |
| container_title | Clinical Epileptology |
| container_volume | 37 |
| creator | Muhle, Hiltrud Kurlemann, Gerhard Lehmann, Irene Hamer, Hajo Mayer, Thomas Potschka, Heidrun Schubert-Bast, Susanne Strzelczyk, Adam Pringsheim, Milka |
| description | Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is generally well tolerated and to date has shown no cardiac side effects such as valve insufficiency or pulmonary hypertension in the clinical development program. However, children may experience a loss of appetite and should be closely monitored for weight loss, and sedation was observed in several overweight patients due to rapid dosage titration; therefore, a slower dosage increase than recommended might be needed for children and adults. Drug interactions should be considered before and during therapy, and dosage reductions are necessary when the medication is used in combination with stiripentol. Furthermore, bromide levels could increase with this medication. Contact with the patient or their relatives is important to determine the general state of health, potential movement disturbances, and seizure frequency so as to allow for timely dosage adjustments during the titration phase. |
| doi_str_mv | 10.1007/s10309-023-00646-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2928458383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928458383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-b51a58efb54af770f0ccc5f519c06b58e3278f6f8e2a2ddf4ce3eb93ec33ae803</originalsourceid><addsrcrecordid>eNp9kMFKxDAQhosouKz7Ap4CnquTpGkTb7LqKix4UfAW0nSiXbppTVp1b76Db-iTWF3Rm6cZmO__B74kOaRwTAGKk0iBg0qB8RQgz_JU7CQTpjKZUhBy93fP7veTWYwrAGBSZZyrSaIv0btmCGZdeyS1J7apfW1NQ7pgbF9bPCUeX0j_iMF0G9J2fd164tpAzoN5xp4YX5Elet--fry9L0zszdCTuPFVaNcYD5I9Z5qIs585Te4uL27nV-nyZnE9P1umllPVp6WgRkh0pciMKwpwYK0VTlBlIS_HC2eFdLmTyAyrKpdZ5FgqjpZzgxL4NDna9nahfRow9nrVDsGPLzVTTGZCcslHim0pG9oYAzrdhXptwkZT0F8u9dalHl3qb5dajCG-DcUR9g8Y_qr_SX0CcH15qQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2928458383</pqid></control><display><type>article</type><title>Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes</title><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Muhle, Hiltrud ; Kurlemann, Gerhard ; Lehmann, Irene ; Hamer, Hajo ; Mayer, Thomas ; Potschka, Heidrun ; Schubert-Bast, Susanne ; Strzelczyk, Adam ; Pringsheim, Milka</creator><creatorcontrib>Muhle, Hiltrud ; Kurlemann, Gerhard ; Lehmann, Irene ; Hamer, Hajo ; Mayer, Thomas ; Potschka, Heidrun ; Schubert-Bast, Susanne ; Strzelczyk, Adam ; Pringsheim, Milka</creatorcontrib><description>Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is generally well tolerated and to date has shown no cardiac side effects such as valve insufficiency or pulmonary hypertension in the clinical development program. However, children may experience a loss of appetite and should be closely monitored for weight loss, and sedation was observed in several overweight patients due to rapid dosage titration; therefore, a slower dosage increase than recommended might be needed for children and adults. Drug interactions should be considered before and during therapy, and dosage reductions are necessary when the medication is used in combination with stiripentol. Furthermore, bromide levels could increase with this medication. Contact with the patient or their relatives is important to determine the general state of health, potential movement disturbances, and seizure frequency so as to allow for timely dosage adjustments during the titration phase.</description><identifier>ISSN: 2948-104X</identifier><identifier>ISSN: 2948-1058</identifier><identifier>EISSN: 2948-1058</identifier><identifier>EISSN: 2948-104X</identifier><identifier>DOI: 10.1007/s10309-023-00646-5</identifier><language>eng</language><publisher>Heidelberg: Springer Medizin</publisher><subject>Amphetamines ; Appetite loss ; Body weight loss ; Convulsions & seizures ; Disease management ; Dosage ; Drug dosages ; Drug interaction ; Epilepsy ; Fenfluramine ; Medicine ; Medicine & Public Health ; Nervous system ; Neurology ; Patients ; Pilot projects ; Seizures ; Serotonin ; Stiripentol ; Titration ; Weight control ; Übersichten</subject><ispartof>Clinical Epileptology, 2024-02, Vol.37 (1), p.68-78</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-b51a58efb54af770f0ccc5f519c06b58e3278f6f8e2a2ddf4ce3eb93ec33ae803</citedby><cites>FETCH-LOGICAL-c319t-b51a58efb54af770f0ccc5f519c06b58e3278f6f8e2a2ddf4ce3eb93ec33ae803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10309-023-00646-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2928458383?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,21367,27901,27902,33721,41464,42533,43781,51294</link.rule.ids></links><search><creatorcontrib>Muhle, Hiltrud</creatorcontrib><creatorcontrib>Kurlemann, Gerhard</creatorcontrib><creatorcontrib>Lehmann, Irene</creatorcontrib><creatorcontrib>Hamer, Hajo</creatorcontrib><creatorcontrib>Mayer, Thomas</creatorcontrib><creatorcontrib>Potschka, Heidrun</creatorcontrib><creatorcontrib>Schubert-Bast, Susanne</creatorcontrib><creatorcontrib>Strzelczyk, Adam</creatorcontrib><creatorcontrib>Pringsheim, Milka</creatorcontrib><title>Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes</title><title>Clinical Epileptology</title><addtitle>Clin Epileptol</addtitle><description>Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is generally well tolerated and to date has shown no cardiac side effects such as valve insufficiency or pulmonary hypertension in the clinical development program. However, children may experience a loss of appetite and should be closely monitored for weight loss, and sedation was observed in several overweight patients due to rapid dosage titration; therefore, a slower dosage increase than recommended might be needed for children and adults. Drug interactions should be considered before and during therapy, and dosage reductions are necessary when the medication is used in combination with stiripentol. Furthermore, bromide levels could increase with this medication. Contact with the patient or their relatives is important to determine the general state of health, potential movement disturbances, and seizure frequency so as to allow for timely dosage adjustments during the titration phase.</description><subject>Amphetamines</subject><subject>Appetite loss</subject><subject>Body weight loss</subject><subject>Convulsions & seizures</subject><subject>Disease management</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Drug interaction</subject><subject>Epilepsy</subject><subject>Fenfluramine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Patients</subject><subject>Pilot projects</subject><subject>Seizures</subject><subject>Serotonin</subject><subject>Stiripentol</subject><subject>Titration</subject><subject>Weight control</subject><subject>Übersichten</subject><issn>2948-104X</issn><issn>2948-1058</issn><issn>2948-1058</issn><issn>2948-104X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kMFKxDAQhosouKz7Ap4CnquTpGkTb7LqKix4UfAW0nSiXbppTVp1b76Db-iTWF3Rm6cZmO__B74kOaRwTAGKk0iBg0qB8RQgz_JU7CQTpjKZUhBy93fP7veTWYwrAGBSZZyrSaIv0btmCGZdeyS1J7apfW1NQ7pgbF9bPCUeX0j_iMF0G9J2fd164tpAzoN5xp4YX5Elet--fry9L0zszdCTuPFVaNcYD5I9Z5qIs585Te4uL27nV-nyZnE9P1umllPVp6WgRkh0pciMKwpwYK0VTlBlIS_HC2eFdLmTyAyrKpdZ5FgqjpZzgxL4NDna9nahfRow9nrVDsGPLzVTTGZCcslHim0pG9oYAzrdhXptwkZT0F8u9dalHl3qb5dajCG-DcUR9g8Y_qr_SX0CcH15qQ</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Muhle, Hiltrud</creator><creator>Kurlemann, Gerhard</creator><creator>Lehmann, Irene</creator><creator>Hamer, Hajo</creator><creator>Mayer, Thomas</creator><creator>Potschka, Heidrun</creator><creator>Schubert-Bast, Susanne</creator><creator>Strzelczyk, Adam</creator><creator>Pringsheim, Milka</creator><general>Springer Medizin</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20240201</creationdate><title>Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes</title><author>Muhle, Hiltrud ; Kurlemann, Gerhard ; Lehmann, Irene ; Hamer, Hajo ; Mayer, Thomas ; Potschka, Heidrun ; Schubert-Bast, Susanne ; Strzelczyk, Adam ; Pringsheim, Milka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-b51a58efb54af770f0ccc5f519c06b58e3278f6f8e2a2ddf4ce3eb93ec33ae803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Amphetamines</topic><topic>Appetite loss</topic><topic>Body weight loss</topic><topic>Convulsions & seizures</topic><topic>Disease management</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Drug interaction</topic><topic>Epilepsy</topic><topic>Fenfluramine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Patients</topic><topic>Pilot projects</topic><topic>Seizures</topic><topic>Serotonin</topic><topic>Stiripentol</topic><topic>Titration</topic><topic>Weight control</topic><topic>Übersichten</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muhle, Hiltrud</creatorcontrib><creatorcontrib>Kurlemann, Gerhard</creatorcontrib><creatorcontrib>Lehmann, Irene</creatorcontrib><creatorcontrib>Hamer, Hajo</creatorcontrib><creatorcontrib>Mayer, Thomas</creatorcontrib><creatorcontrib>Potschka, Heidrun</creatorcontrib><creatorcontrib>Schubert-Bast, Susanne</creatorcontrib><creatorcontrib>Strzelczyk, Adam</creatorcontrib><creatorcontrib>Pringsheim, Milka</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Clinical Epileptology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muhle, Hiltrud</au><au>Kurlemann, Gerhard</au><au>Lehmann, Irene</au><au>Hamer, Hajo</au><au>Mayer, Thomas</au><au>Potschka, Heidrun</au><au>Schubert-Bast, Susanne</au><au>Strzelczyk, Adam</au><au>Pringsheim, Milka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes</atitle><jtitle>Clinical Epileptology</jtitle><stitle>Clin Epileptol</stitle><date>2024-02-01</date><risdate>2024</risdate><volume>37</volume><issue>1</issue><spage>68</spage><epage>78</epage><pages>68-78</pages><issn>2948-104X</issn><issn>2948-1058</issn><eissn>2948-1058</eissn><eissn>2948-104X</eissn><abstract>Fenfluramine is an antiseizure medication for the treatment of Dravet and Lennox–Gastaut syndromes. This review summarizes the literature on the efficacy and tolerability of fenfluramine and presents recommendations for practical therapeutic management. With regular monitoring, this medication is generally well tolerated and to date has shown no cardiac side effects such as valve insufficiency or pulmonary hypertension in the clinical development program. However, children may experience a loss of appetite and should be closely monitored for weight loss, and sedation was observed in several overweight patients due to rapid dosage titration; therefore, a slower dosage increase than recommended might be needed for children and adults. Drug interactions should be considered before and during therapy, and dosage reductions are necessary when the medication is used in combination with stiripentol. Furthermore, bromide levels could increase with this medication. Contact with the patient or their relatives is important to determine the general state of health, potential movement disturbances, and seizure frequency so as to allow for timely dosage adjustments during the titration phase.</abstract><cop>Heidelberg</cop><pub>Springer Medizin</pub><doi>10.1007/s10309-023-00646-5</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2948-104X |
| ispartof | Clinical Epileptology, 2024-02, Vol.37 (1), p.68-78 |
| issn | 2948-104X 2948-1058 2948-1058 2948-104X |
| language | eng |
| recordid | cdi_proquest_journals_2928458383 |
| source | SpringerLink Journals - AutoHoldings; ProQuest Central |
| subjects | Amphetamines Appetite loss Body weight loss Convulsions & seizures Disease management Dosage Drug dosages Drug interaction Epilepsy Fenfluramine Medicine Medicine & Public Health Nervous system Neurology Patients Pilot projects Seizures Serotonin Stiripentol Titration Weight control Übersichten |
| title | Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fenfluramine%20in%20clinical%20practice:%20new%20therapy%20option%20for%20Dravet%20and%20Lennox%E2%80%93Gastaut%20syndromes&rft.jtitle=Clinical%20Epileptology&rft.au=Muhle,%20Hiltrud&rft.date=2024-02-01&rft.volume=37&rft.issue=1&rft.spage=68&rft.epage=78&rft.pages=68-78&rft.issn=2948-104X&rft.eissn=2948-1058&rft_id=info:doi/10.1007/s10309-023-00646-5&rft_dat=%3Cproquest_cross%3E2928458383%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2928458383&rft_id=info:pmid/&rfr_iscdi=true |